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ABSTRACT
Objective:This study aims to determine the prevalence of antinuclear antibodies in pregnant women with bad obstetric history (BOH) against healthy 
multigravid women in and around Tirunelveli district
Methods: This is a case-control study comprising 60 antenatal women with BOH against 60 multiparous pregnant women with no history of abortions. 
Antinuclear antibodies (ANA) were detected using indirect immunofluorescence with Hep-2 cell substrate, and enzyme-linked immunosorbent assay 
(ELISA).
Results: Among BOH cases 19 (82.6%), 18 (78.26%) were positive by ELISA and indirect fluorescence antibody test (IFAT) method, respectively. 
Among controls, 4(17.39%) and 5(21.73%) individuals were positive by ELISA and IFAT methods, respectively. Of the 18 positives, homogenous 
pattern was most common followed by anticentromere pattern, fine speckled and coarse speckled pattern
Conclusion: IFAT is considered to be gold standard in the diagnosis of autoimmune disorders, but ELISA appears to be a suitable simple alternative 
for testing rheumatological disorders.
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INTRODUCTION
Autoimmune disorders are 6-10 times more common among women 
than men [1], and they are likely to have their onset during the 
reproductive years. Screening of patients for subclinical autoimmune 
disease has been a matter of controversy for years. The causes of 
recurrent fetal wastage are multifactorial, and sometimes more than 
one factor may be present in a case, which could be recurrent or 
nonrecurrent. Pregnancy is faced with a number of self and foreign 
antigens that modulate the immune system of the mother. If immune 
response of mother is altered, frequent abortions may result.
Presence of autoantibodies causes rejection of early pregnancy in 30% 
of women [2,3]. Antibodies responsible are antinuclear antibodies and 
antiphospholipid antibodies: Lupus anticoagulant, and anticardiolipin 
antibodies. Antinuclear antibodies may interfere with the formation 
and maturation of placenta which would eventually lead to an early 
fetal loss. Histone proteins and deoxyribonucleic acid induce tissue 
development. Formation of antibodies against these histone proteins 
may lead to activation of the autoimmune process in mother and 
thereby end up in abortion.
There are various techniques for antinuclear antibodies (ANA) 
detection. Indirect immunofluorescence continues to be a basic 
technique in autoimmunity studies. Autoantibodies give characteristic 
fluorescence images called fluorescent patterns. It is inexpensive and 
easy to perform with a high degree of sensitivity and specificity and is 
considered to be gold standard, but some results may be misinterpreted. 
As it detects several different antibodies, cross-reactions can occur. 
Immunofluorescence can give false positive result in up to 3% of the 
population [4].
Enzyme-linked immunosorbent assay (ELISA) can also be used for 
diagnosis of autoantibodies, there are two types of ELISA methods 
employed for ANA testing. The generic assay is the one which detects 
ANA of broad specificity and the other is called specific antigen 
assay that detects a particular autoantibody as it reacts with single 
autoantigen. ELISA is highly specific and sensitive and decreases 
the time involved in screening a large number of patient samples. 
ELISA is simple to perform, can be automated and it does not require 
person with high technical skill who could recognize microscopic 
patterns.
MATERIALS AND METHODS
Setting of the study
This study was conducted from the period of November 2011 to June 
2012. The study population comprises mainly of pregnant women from 
19 to 40 years, attending antenatal clinic and inpatients in Obstetrics 
and Gynecology Department, Tirunelveli Medical College Hospital. 
This is a case-control study comprising an equal number of cases and 
controls, each comprising 60 women of reproductive age group.
Study population




death, or early neonatal deaths.
The population was carefully selected that women in study group have 
no live issues. The control group comprises 60 multiparous pregnant 
women from age group 19 to 40 years, with no history of abortions.
Exclusion criteria
It includes women with history of heart disease, anemia, renal failure, 
Rh incompatibility, history of sexually transmitted diseases, or TORCH 
infections, uterine fibroids, endometriosis, pelvic inflammatory 
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disease, uterine anomalies and septate uterus, and bicornuate uterus. 
Institutional ethical clearance was obtained.
Informed written consent was obtained from all pregnant women 
involved in the study. Details of history and physical examination findings 
were noted. In all patients hemoglobin, blood group, fasting blood sugar, 
ultrasonography, and TORCH test were done by standard methods.
Methodology
Under strict aseptic precautions, 3-5 ml blood was collected from 
both study group and control group and subjected to indirect 
immunofluorescence using Hep-2 cells (BioSystems Pvt. Ltd.,). Serum 
ANA bind to the corresponding antigens present in Hep-2 cells. The 
resulting antigen-antibody complexes are detected by means of a 
fluorescein-labeled anti-human immunoglobulin (IgG) and visualized 
with the aid of a fluorescence microscope.
The serum samples were also subjected to ELISA. Specific ANA in the 
sample bind to the antigens immobilized on the microwell surface. 
In a second incubation, a conjugate of horseradish peroxidase-
labeled IgG’s to human IgG binds to surface-bound antibodies. Finally, 
3,3’,5,5’-tetramethylbenzidine with hydrogen peroxidase was added 
to each well as enzyme substrate and, after color development, the 
enzymatic reaction was stopped with hydrochloric acid. The yellow 
product formed was measured in terms of absorbance units at 450nm, 
and its proportional to the amount of antibodies present.
Statistics
Data regarding the cases and controls were described in terms of 
percentages. Sensitivity, specificity, positive predictive value (PPV), 
and negative predictive value (NPV) of ELISA were done. The cases and 
controls were statistically analyzed for significance by Chi-squared test. 
The Chi-squared test was calculated for the analytic assessment by SPSS 
20 version software. The differences were considered to be statistically 
significant when the p<0.05.
RESULTS
Table 1 shows age-wise distribution of bad obstetric history (BOH) cases 
and antinuclear antibodies positive among them. Of the 7 samples tested 
from age group 16 to 20 years, 1 sample is positive and remaining were 
negative. Of the 13 cases tested 3 were positive, and 10 were negative in 
the age group 21-25 years. From 26 to 30 years, 21 samples were tested, 
of which 8 samples were positive, and remaining 13 were tested negative. 
12 individuals were tested from age group 31 to 35 years, 6 were positive 
and remaining 6 were negative. Among 7 cases tested from age group 36 
to 40 years, none were positive. The mean age among cases is 28 years.
Table 2 shows the distribution of ANA positivity among cases and 
controls. Among 60 women with BOH, 18 (30%) were found to be 
positive. Among controls 5 (8.3%) women were positive.
Among 60 cases with BOH, 18 (30%) tested positive for ANA by 
immunofluorescence and 42 (70%) were ANA negative. Of the total 
60 multigravid women, 5 (8.3%) of them tested positive for ANA 
by indirect fluorescence antibody test (IFAT), and the remaining 
55 (91.66%) were negative. The association between women with BOH 
and multigravid controls, using immunofluorescence was considered to 
be statistically significant (Table 3).
Table 4 shows the distribution of HEp-2 cell pattern among the 23 IFAT 
positives which include both cases and controls. Of the 18 positives, 
homogenous pattern was seen in 8 (44.44%), anticentromere pattern 
in 6 (26.08%), fine speckled in 4 (17.39%), coarse speckled pattern in 
3 (13.04%), vimentin and nuclear rim pattern were seen in 2 (8.69%) 
patients.
Among 60 cases with BOH, 19 (31.6%) tested positive for ANA by ELISA 
and 41 (68.33%) were ANA negative. Of the total 60 multigravid women, 
4 (6%) of them tested positive for ANA by ELISA, and the remaining 
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56 (93.33%) were negative. The association between ANA positivity, 
for women with BOH and controls were considered to be statistically 
significant (Table 5).
Table 6 compares ANA positivity among cases and controls by both 
ELISA and IFAT method. Among BOH cases 19 (82.6%), 18 (78.26%) 
were positive by ELISA and IFAT method, respectively. Among controls, 
4 (17.39%) and 5 (21.73%) individuals were positive by ELISA and 
IFAT methods, respectively.
ELISA reported one more women with BOH as ANA positive, which 
IFAT failed to detect. Among controls, ELISA missed one sample as ANA 
positive while IFAT reported as positive.
ELISA test was evaluated for its sensitivity and specificity against IFAT, 
gold standard test. Table 7 shows sensitivity, specificity, PPV, and NPV of 
ELISA are 94.7%, 95.12%, 90%, and 97.5%, respectively.
DISCUSSION
In this study, the mean age among cases and controls is around 
28 years. Patton [5] tested sera from 136 women (84 pregnant and 
52 nonpregnant) for antibodies directed against nuclear antigens, 
the mean ages of the two groups were 32 and 26 years, respectively. 
A study from Sweden also reported the similar findings were the 
risk of abortions is 8.7% at age 24 and rises up to 24.7% at the age 
of 35.
In this study, antinuclear antibodies were found in 18 (30%) women 
with RPL and 5 (8.3%) in the control group, which is comparable to 
the study conducted by Garcia et al. [6] and Nakatsuka et al. [7] where 
the prevalence of ANA among women with BOH was 30% and 43.5% 
when compared to women in control groups which were about 6.6% 
and 22.4%, respectively.
The occurrence of ANA in normal pregnancy has been variably reported 
to range from 1 to 53%. In this study 5 (8.3%) women were found to 
be positive for ANA which is in accordance with the study conducted 
by Farnam et al. [8] where he reported ANA in about 10.7% pregnant 
women in low titers. This indicates that ANA can be found in normal 
pregnancy due to some infectious etiology and not only because of 
collagenosis.
In this study, 23 women were positive for antinuclear antibodies 
including 18 (30%) of women with BOH and 5 (8.3%) controls by 
indirect immunofluorescence using HEp-2 cell as substrate. Similar 
findings are reported by Garcia et al. [6], Xu et al. [9].
Among the nuclear patterns, the most frequent consist of homogeneous/
peripheral fluorescence (DNA, deoxyribonucleoprotein, and histones) 
and speckled fluorescence (RNP, Sm, Ro/SSA, and La/SSB); the relatively 
less frequent patterns include the centromeric (CENP-A, CENP-B, and 
CENP-C), and cytoplasmic patterns. Our study revealed homogenous 
pattern in 8 (44.44%), followed by speckled pattern in 7 (38.85%), and 
anticentromere pattern in 6 (26.08%). Cytoplasmic pattern was seen 
only in 1 (4.65%) individual. The nuclear patterns were comparable 
with the findings of Satoh et al. [10] in the USA, and Afman [11] in South 
Africa.
Table 1: Age-wise distribution of BOH women with ANA 
positivity
S. No. Age in 
years







1 16-20 7 1 (5.55) 6 (14.28)
2 21-25 13 3 (16.66) 10 (23.80)
3 26-30 21 8 (44.44) 13 (30.95)
4 31-35 12 6 (33.55) 6 (14.28)
5 36-40 7 - 7 (16.69)
Total 60 18 (100) 42 (100)
ANA: Antinuclear antibodies, BOH: Bad obstetric history
Table 2: ANA positivity among cases and controls
Samples Total number ANA positivity
n (%)
Cases 60 18 (30)
Controls 60 5 (8.3)
Table 4: Distribution of HEp-2 cell pattern among IFAT positives
HEp-2 cell pattern Number of positives (%)
Homogenous 8 (44.44)
Anticentromere 6 (26.08)
Fine speckled 4 (17.39)
Coarse speckled 3 (13.04)
Others vimentin, nuclear rim 2 (8.69)
IFAT: Indirect fluorescence antibody test
Table 6: Comparison of ELISA and IFAT for ANA positivity among 
cases and controls
Study population Number of positives (%)
ELISA IFAT
Cases (n=60) 19 (82.6) 18 (78.26)
Controls (n=60) 4 (17.39) 5 (21.73)
p<0.05 not significant. ELISA: Enzyme-linked immunosorbent assay, 
IFAT: Indirect fluorescence antibody test, and ANA: Antinuclear antibodies




Positive 18 2 20
Negative 1 39 40
Total 19 41
ELISA: Enzyme-linked immunosorbent assay, ANA: Antinuclear antibodies
Table 3: Evaluation of ANA among cases and controls using 
immunofluorescence
Samples n (%)
IFAT (+) IFAT (-)
Cases (n=60) 18 (30) 42 (70)
Controls (n=60) 5 (8.3) 55 (91.66)
Total 23 (38.3) 97
p<0.001 (statistically significant). IFAT: Indirect fluorescence antibody test
Table 5: Evaluation of seropositivity among BOH cases and 
controls using ELISA
Samples Cases (%)
ELISA (+) ELISA (-)
Cases (n=60) 19 (31.6) 41 (68.33)
Controls (n=60) 4 (6) 56 (93.33)
Total 23 97
p<0.001 (statistically significant). ELISA: Enzyme-linked immunosorbent assay, 
BOH: Bad obstetric history
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In our study among 120 patients tested for ANA, 19 (31.8%) of women 
with BOH and 4 (6%) of controls were reported to be positive by ELISA. 
A study from Saudi Arabia [12], has the similar findings. 
In this study, antinuclear antibodies were positive in 18 (30%) cases 
by IFAT and 19 (31.6%) cases by ELISA. Among the control, population 
tested for antinuclear antibodies 5 (8.3%), and 4 (6%) samples were 
reported to be positive by IFAT and ELISA, respectively. The sensitivity, 
specificity, PPV, and NPV of ELISA for antinuclear antibodies were found 
to be 94.7%, 95.12%, 90%, and 97.5%, respectively.
A study conducted in Japan by Kumagai and Hayashi [13] screened 
257 healthy subjects between COBAS-ANA and IF-ANA. The sensitivity 
and specificity of COBAS-ANA were 84% and 94%, respectively. 
Divate et al. [14], investigated the sera from 96 patients and found 
the sensitivity, specificity, PPV, and NPV of ELISA were 90.7%, 85.7%, 
89.1%, and 87.8%, respectively.
IFAT is considered as gold standard method for ANA detection, but this 
technique has some drawbacks. There are chances for false positive 
results in up to 3% of normal population. ANA levels tend to rise and 
fall, and sometimes being undetectable when symptoms are mild 
or when patient is at remission. Other factors which could lower the 
sensitivity of IFAT include variations in the substrate and subjective 
interpretation. In recent times, there have been some advances in 
standardization of the IFAT method which includes automation of 
the analytic procedure and recognition of the immunohistochemical 
pattern by way of computerized systems. However, these things are 
beyond scope for developing nations.
ELISA assay offers a suitable alternative as a preliminary investigation 
to exclude negative ANA sera. ELISA is technically simpler, and faster 
which could be useful in laboratories which screens large numbers 
of samples among which many could be ANA negative. The major 
advantage of ELISA is that it is not subjective in nature and is also more 
economical than the IFAT. However, the problem lies in samples with 
gray zone where each laboratory should identify a suitable cut-off ANA 
index which would segregate these samples from significantly positive 
ones. Retesting by the standard IFAT should be done for all low positive 
“gray zone” samples for confirmation of ANA positivity.
The ideal method should fulfill criteria of clinical sensitivity and high 
specificity, precision and accuracy, ease of execution, limited use of 
technology, quick availability, and contained costs [15]. At present, no 
method exists that fulfills all these requirements.
Thus, women without an autoimmune disorder history, but with 
complications during pregnancy, have a raised number of autoantibodies. 
Further research in this topic that the occurrence of autoantibodies is 
transient particularly limited to pregnancy or postpartum or predictive 
of future immune related diseases are to be done in near future so that 
we prevent recurrent fetal wastage.
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